gavel_istock-517976804_avosb-
Avosb / iStockphoto.com
6 November 2018Big Pharma

German patent court publishes reasoning in Gilead SPC dispute

Germany’s Federal Patent Court (Bundespatentgericht, BpatG) has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate (SPC) for HIV/AIDS treatment Truvada,

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Americas
10 January 2019   Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.

More on this story

Big Pharma
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Americas
10 January 2019   Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.

More on this story

Big Pharma
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.
Big Pharma
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Americas
10 January 2019   Gilead Sciences, a biopharmaceutical company based in the US, has entered into a licensing and collaboration agreement with South Korean healthcare company Yuhan.